雷珠单抗治疗视网膜中央静脉阻塞并发黄斑水肿的报告

目的：：探讨玻璃体腔内注射雷珠单抗治疗视网膜中央静脉阻塞并发黄斑水肿的临床疗效。方法：选取2015-03/09我院收治的视网膜中央静脉阻塞并发黄斑水肿患者30例30眼行雷珠单抗玻璃体腔内注射,1次/mo,治疗1~3mo,治疗结束后随诊3mo,比较患者注射后最佳矫正视力、眼压、黄斑中心凹视网膜厚度、黄斑水肿消退率及眼底荧光血管造影检查结果。结果：随着雷珠单抗注射次数的增加,患者的最佳矫正视力逐渐提高(P<0.05),黄斑中心凹视网膜厚度明显下降(P<0.05),眼压与治疗前比较并无明显变化(P>0.05)。第1、2、3次注射后患者黄斑水肿消退率分别为47%、68%、94%。结论：玻璃体腔内注射雷珠单抗能够有效缓解视网膜中央静脉阻塞继发的黄斑水肿,明显改善患者的视力。

Report of intravitreal injection of Ranibizumab for macular edema caused by central retinal vein occlusion

AlM:To investigate the clinical effect of intravitreal injection of Ranibizumab for macular edema caused by central retinal vein occlusion( CRVO) .METHODS:Selected 30 patients (30 eyes) from March~September 2015 in our hospital with CRVO complicated by macular edema were treated with intravitreal injection of ranibizumab, 1 time per month, 1 ~3mo as one course. After treatments, all patients were followed up for 3mo. The best corrected visual acuity ( BCVA ) , intraocular pressure ( lOP ) , central macular thickness and macular edema regressive rate and fundus fluorescein angiography were compared and analyzed. RESULTS: With the increase of injection times of ranibizumab, BCVA in patients had a gradual increase (P<0. 05). Central macular thickness significantly decreased (P<0. 05), and lOP had no significant change (P>0. 05). After the 1st, 2nd and 3th injection, the macular edema regressive rates were 47%, 68%, 94%.CONCLUSlON:lntravitreal injection of ranibizumab can significantly relieve the macular edema caused by CRVO and improve BCVA of the patients.